Exchange losses and legal expenses drag down Orchid's Q3
This article was originally published in Scrip
Executive Summary
Orchid Chemicals and Pharmaceuticals has reported a net loss of Rs168.6 million ($3.6 million) for the third quarter ended December 31st, 2009, against a loss of Rs63.1 million for the same period in the previous year. The figure was dragged down by exchange rate losses and legal expenses incurred for a challenge concerning piperacillin and tazobactam for injection (a generic version of Wyeth's Zosyn) in the US.